Back to today’s briefing

Story perspectives

Innate Pharma's NK Cell Engagers Transform Lymphoma Treatment

1/10/2025

50 9

Summary

Story summary

Innate Pharma is pioneering NK cell engagers, offering a groundbreaking alternative to traditional T cell therapies for lymphoma. These innovative molecules forge "molecular bridges" between immune cells and cancer cells, amplifying the body’s fight against cancer. Promising early studies highlight their potential against B cell non-Hodgkin lymphoma, as Phase 1 clinical trials continue to evaluate their safety and effectiveness.

1 of 1

Story summary

Innate Pharma is pioneering NK cell engagers, offering a groundbreaking alternative to traditional T cell therapies for lymphoma. These innovative molecules forge "molecular bridges" between immune cells and cancer cells, amplifying the body’s fight against cancer. Promising early studies highlight their potential against B cell non-Hodgkin lymphoma, as Phase 1 clinical trials continue to evaluate their safety and effectiveness.